USPTO serial 79286017
CELLVIE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- FICKES, JERI J
- Law office
- TMEG LAW OFFICE 107 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with CELLVIE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Bruce Londa
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Preparations for medical purposes employing mitochondria; cardiovascular treatment preparations employing mitochondria; cardiovascular pharmaceuticals employing mitochondria used in treating arrhythmias; pharmaceutical and biological preparations for the treatment of cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies, tumors or diabetes mitochondria for transplant purposes for medical use; pharmaceutical and biological preparations for the application of mitochondria transplantation for medical purposes in vessel and organ transplantations; implantable living tissue and mitochondria for the promotion of tissue growth, for medical use; mitochondria, for medical use; biological tissue cultures containing mitochondria for medical purposes; pharmaceutical and biological preparations containing mitochondria for tissue regeneration and protection for medical purposes; living cell components, namely, mitochondria, including genetically-modified mitochondria or pharmaceutically treated mitochondria, for medical use in humans and veterinary use in animals | ACTIVE | — |
| 010 | Prosthetic tissues based on mitochondria for parietal, vascular and visceral use; medical apparatus and devices for the processing of tissue- or cell-samples for the isolation of mitochondria or other cell components, namely, nucleus, ribosomes, rough endoplasmic reticulum, smooth endoplasmic reticulum, golgi apparatus, vacuole, chloroplasts, peroxisome, lysosome, centrosome, centriole, cilium, microvillus, cytosol, cytoskeleton, microtubules, filaments, exosomes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), micro RNA (mRNA), transfer RNA (tRNA), nucleic acid, cell membrane, plasma membrane and secretory vesicles from muscle tissue or other human or animal tissues, as well as from cells and cell cultures; filter for the isolation of cell components, namely, mitochondria, nucleus, ribosomes, rough endoplasmic reticulum, smooth endoplasmic reticulum, golgi apparatus, vacuole, chloroplasts, peroxisome, lysosome, centrosome, centriole, cilium, microvillus, cytosol, cytoskeleton, microtubules, filaments, exosomes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), micro RNA (mRNA), transfer RNA (tRNA), nucleic acid, cell membrane, plasma membrane and secretory vesicles from cells for medical purposes; medical apparatus and devices for the transplantation or injection of cells or cell component, namely, mitochondria, nucleus, ribosomes, rough endoplasmic reticulum, smooth endoplasmic reticulum, golgi apparatus, vacuole, chloroplasts, peroxisome, lysosome, centrosome, centriole, cilium, microvillus, cytosol, cytoskeleton, microtubules, filaments, exosomes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), micro RNA (mRNA), transfer RNA (tRNA), nucleic acid, cell membrane, plasma membrane and secretory vesicles in humans or animals | ACTIVE | — |
| 042 | Scientific and technological services, namely, scientific and clinical research, analysis and testing in the field of mitochondrial isolation or transplantation; scientific and clinical research and development services in the field of mitochondria; conducting clinical trials for others in the field of cardiovascular diseases, ischemia-and reperfusion-injuries, heart transplantations, tumor treatments, mitochondrial myopathies analysis of human tissues for scientific and clinical research relating to mitochondria; scientific and clinical research, analysis and testing services relating to the isolation and cultivation of human and animal mitochondria | ACTIVE | — |
| 044 | Medical testing services for diagnostic and disease treatment purposes relating to cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies and tumors; medical analysis of human or animal tissues for mitochondria transplant treatment purposes of cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies and tumors; medical analysis of cells and cell components in relation to mitochondria for diagnostic and treatment purposes of cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies and tumors | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Cellvie UG (haftungsbeschränkt)
- Other trademarks owned by cellvie Inc.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named CELLVIE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 20, 2024 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Nov 7, 2022 | FINT | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 17, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 15, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 9, 2022 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 22, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 22, 2021 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Oct 15, 2021 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 15, 2021 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Mar 29, 2021 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 29, 2021 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 29, 2021 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 5, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 5, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 5, 2021 | ALIE | ASSIGNED TO LIE | — |
| Dec 3, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 16, 2020 | CORR | CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED | — |
| Jul 31, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 17, 2020 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Jun 29, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 29, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 29, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 28, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 26, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 22, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| May 22, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 21, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |